Investigating the effect of adding memantine to a long-acting stimulant on executive function deficits in adolescents with attention deficit hyperactivity disorder

Determining and comparing the total score of the self-report scale of attention deficit hyperactivity disorder (ASRS) in adolescents in the two study groups, before and after the intervention

A controlled, parallel-group, triple-blind, randomized, phase 3 clinical trial on 44 patients. Endnote software was used for randomization.

The study is a triple-blind randomized clinical trial. Patients, therapists, and statistical consultants are unaware of the control and intervention groups. The target population of the study is adolescents aged 12 to 18 years, and patients in both the intervention and control groups are being treated with long-acting methylphenidate (stimulant) within the therapeutic dose range.

Diagnosis of ADHD by a psychiatrist using a questionnaire Existence of functional deficits in the adolescent Age 12 to 18 years Normal intelligence quotient using an IQ test Exclusion criteria: Presence of major medical disorders (heart disease, diabetes, asthma, renal failure, etc.) Presence of comorbid psychiatric disorders that require pharmacological interventions. Use of another medication in addition to a long-acting stimulant

In the intervention group receive the drug memantine + long-acting stimulant. The control group receives placebo + long-acting stimulant.

The severity of executive dysfunction; the severity of attention deficit and hyperactivity

Patients who have a history of visiting the clinic and have been treated with a long-acting stimulant, if they are eligible, are included in the study as patients. This method is called sequential sampling. After identifying the study subjects, the first two people show us a block. Then, we randomly assign the subjects in each block to the usual treatment + memantine group (A) and the usual treatment + placebo group (B). The next two people are also randomly assigned to group A and the other to group B until we reach a sufficient sample size.

The therapist only gives the patient the medicine they need for a month based on whether the patient belongs to group A or B, but he is not aware of the contents of the medicine packets A or B, and finally, the statistical consultant is not informed of the patient group when performing statistical calculations.